The world’s first combination seasonal influenza and COVID-19 vaccine, Moderna’s mCombriax, has received marketing ...

Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat. CAMBRIDGE, MA / ACC ...

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...

April 21 (Reuters) - Moderna said on Tuesday the European Commission had approved its combination vaccine for the prevention ...

Moderna (NasdaqGS:MRNA) plans to present Phase 1/2 data for its mRNA-4359 cancer antigen therapy combined with pembrolizumab ...

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

The Department of Health and Human Services had canceled hundreds of millions of dollars in funding previously committed help ...

A new effort to prepare for future bird flu outbreaks is moving forward, despite a major funding setback. The American pharmaceutical and biotechnology company Moderna has initiated a large clinical ...

April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, its investigational seasonal ...

Moderna, Revolution Medicines and Zymeworks record wins in melanoma, lung and breast cancers, while BeOne swings and misses ...

Moderna stock gains as the company begins dosing in a Phase 3 trial designed to evaluate its messenger RNA-based bird flu ...

April 21 (Reuters) - Moderna said on Tuesday it had started a late-stage study of its experimental bird flu vaccine in the ...